Endogenous cardioprotective agents: Role in pre and postconditioning

Current Drug Targets

Volumn 16, Issue 8, 2015, Pages 843-867

  Penna, Claudia ^a,d   Granata, Riccarda ^b   Tocchetti, Carlo Gabriele ^c   Gallo, Maria Pia ^a,d   Alloatti, Giuseppe ^a,d   Pagliaro, Pasquale ^a,d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d National Institute for Cardiovascular Research   (Italy)

Author keywords

Cardioprotection; Chromogranin A derivatives; Exosomes; Ghrelin associated peptides; GPCR activators; Growth factors; Ischemia reperfusion; Tyrosine kinase receptor activators

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADIPOCYTOKINE; BRADYKININ; CASPASE 3; CHROMOGRANIN A; CONNEXIN 43; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE REGULATED PROTEIN 78; GROWTH HORMONE RELEASING FACTOR; MATRIX METALLOPROTEINASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SPHINGOSINE 1 PHOSPHATE; STAT PROTEIN; STAT3 PROTEIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNINDEXED DRUG; CARBON MONOXIDE; CARDIOTONIC AGENT; GASOTRANSMITTER; HYDROGEN SULFIDE; NITRIC OXIDE;

APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DOWN REGULATION; HEART ARRHYTHMIA; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UPREGULATION; ANIMAL; HEART INFARCTION PREVENTION; METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PROCEDURES;

ANIMALS; CARBON MONOXIDE; CARDIOTONIC AGENTS; GASOTRANSMITTERS; HUMANS; HYDROGEN SULFIDE; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE;

EID: 84937533711     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150309115536     Document Type: Article

References (340)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
2. Dawn B, Bolli R. Role of nitric oxide in myocardial preconditioning. Ann N Y Acad Sci 2002; 962: 18-41.
3. Pagliaro P, Gattullo D, Rastaldo R, Losano G. Ischemic preconditioning: from the first to the second window of protection. Life Sci 2001; 69: 1-15.
4. Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 2011; 14: 833-50.
5. Crisafulli A, Melis F, Tocco F, et al. Exercise-induced and nitroglycerin- induced myocardial preconditioning improves hemodynamics in patients with angina. Am J Physiol Heart Circ Physiol 2004; 287: H235-42.
6. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-51.
7. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 2009; 104: 469-83.
8. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-88.
9. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004; 95: 230-2.
10. Penna C, Cappello S, Mancardi D, et al. Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 2006; 101: 168-79.
11. Penna C, Mancardi D, Rastaldo R, Pagliaro P. Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta 2009; 1787: 781-93.
12. Penna C, Perrelli MG, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal 2013; 18: 556-99.
13. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P. The paradigm of postconditioning to protect the heart. J Cell Mol Med 2008; 12: 435-58.
14. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech 2010; 3: 35-8.
15. Xin P, Zhu W, Li J, et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart Circ Physiol 2010; 298: H1819-31. Erratum in: Am J Physiol Heart Circ Physiol 2010; 299: H957.
16. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 2011; 8: 619-29.
17. Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther 2011; 16: 255-9.
18. Tamareille S, Mateus V, Ghaboura N, et al. RISK and SAFE signaling pathway interactions in remote limb ischemic perconditioning in combination with local ischemic postconditioning. Basic Res Cardiol 2011; 106: 1329-39.
19. Bell RM, Yellon DM. Conditioning the whole heart--not just the cardiomyocyte. J Mol Cell Cardiol 2012; 53: 24-32.
20. Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 2012; 32: 1552-62.
21. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008; 8: 207-20.
22. Halestrap AP. Mitochondria and reperfusion injury of the heart -- a holey death but not beyond salvation. J Bioenerg Biomembr 2009; 41: 113-21.
23. Cour M, Gomez L, Mewton N, Ovize M, Argaud L. Postconditioning: from the bench to bedside. J Cardiovasc Pharmacol Ther 2011; 16: 117-30.
24. Inserte J, Barrabés JA, Hernando V, Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res 2009; 83: 169-78.
25. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003; 17: 2328 -30.
26. Tsao PS, Ma X, Lefer AM. Activated neutrophils aggravate endothelial dysfunction after reperfusion of the ischemic feline myocardium. Am Heart J 1992; 123: 1464 -71.
27. Reimer KA, Tanaka M, Murry CE, Richard VJ, Jennings RB. Evaluation of free radical injury in myocardium. Toxicol Pathol 1990; 18: 470-80.
28. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
29. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-8.
30. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-9.
31. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary noreflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv 2010; 3: 695-704.
32. Inserte J, Ruiz-Meana M, Rodríguez-Sinovas A, Barba I, Garcia- Dorado D. Contribution of delayed intracellular pH recovery to ischemic postconditioning protection. Antioxid Redox Signal 2011; 14: 923-39.
33. Simkhovich BZ, Whittaker P, Przyklenk K, Kloner RA. Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Basic Res Cardiol 1995; 90: 397-403.
34. Asimakis GK, Inners-McBride K, Medellin G, Conti VR. Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart. Am J Physiol 1992; 263: H887-94
35. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol 2007; 102: 445-52.
36. Penna C, Rastaldo R, Mancardi D, et al. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 2006; 101: 180-9.
37. Tullio F, Angotti C, Perrelli MG, Penna C, Pagliaro P. Redox balance and cardioprotection. Basic Res Cardiol 2013; 108: 392.
38. Penna C, Angotti C, Pagliaro P. Protein S-nitrosylation in preconditioning and postconditioning. Exp Biol Med (Maywood) 2014; 239: 647-62.
39. Dost T, Cohen MV, Downey JM. Redox signaling triggers protection during the reperfusion rather than the ischemic phase of preconditioning. Basic Res Cardiol 2008; 103: 378-84.
40. Vanden Hoek T, Becker LB, Shao ZH, Li CQ, Schumacker PT. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res 2000; 86: 541-8.
41. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004; 61: 461-70.
42. Liu Y, Yang XM, Iliodromitis EK, et al. Redox signaling at reperfusion is required for protection from ischemic preconditioning but not from a direct PKC activator. Basic Res Cardiol 2008; 103: 54- 9.
43. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007; 12: 217-34.
44. Cohen MV, Downey JM. Ischemic postconditioning: from receptor to end effector. Antioxid Redox Signal 2011; 14: 821-31.
45. Cohen MV, Downey JM. Signaling pathways and mechanisms of protection in pre-and postconditioning: historical perspective and lessons for the future. Br J Pharmacol 2015; 172: 1913-32.
46. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014; 66: 1142-74.
47. Kleinbongard P, Heusch G. Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection? Br J Pharmacol 2015; 172: 2010-25.
48. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118: 1915-19.
49. Pagliaro P, Penna C. Redox signaling and cardioprotection - translatability and mechanism. Br J Pharmacol 2015; 172: 1974-95.
50. Murphy E, Kohr M, Sun J, Nguyen T, Steenbergen C. Snitrosylation: a radical way to protect the heart. J Mol Cell Cardiol 2012; 52: 568-77.
51. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/ reperfusion injury. Cardiovasc Res 2004; 61: 402-13.
52. Leary PJ, Rajasekaran S, Morrison RR, Tuomanen EI, Chin TK, Hofmann PA. A cardioprotective role for platelet activating factor through NOS dependent S-nitrosylation. Am J Physiol Heart Circ Physiol 2008; 294: H2775-84.
53. Grube K, Rüdebusch J, Xu Z, et al. Evidence for an intracellular localization of the adenosine A2B receptor in rat cardiomyocytes. Basic Res Cardiol 2011; 106: 385-96.
54. Garlid KD, Costa AD, Quinlan CL, Pierre SV, Dos Santos P. Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 2009; 46: 858-66.
55. Heinzel FR, Luo Y, Li X, et al. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ Res 2005; 97: 583-6.
56. Srisakuldee W, Jeyaraman MM, Nickel BE, Tanguy S, Jiang ZS, Kardami E. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc Res 2009; 83: 672-81.
57. Soetkamp D, Nguyen TT, Menazza S, et al. S-nitrosation of mitochondrial connexin 43 regulates mitochondrial function. Basic Res Cardiol 2014; 109: 433.
58. Frias MA, Lecour S, James RW, Pedretti S. High density lipoprotein/ sphingosine-1-phosphate-induced cardioprotection: role of STAT3 as part of the SAFE pathway. JAKSTAT 2012; 1: 92-100.
59. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between SAFE and RISK pathways in sphingosine-1-phosphateinduced cardioprotection. Cardiovasc Drugs Ther 2012; 26: 227- 37.
60. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011; 14: 893-907.
61. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011; 109: 1302-8.
62. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010; 105: 771-85.
63. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010; 24: 85-7.
64. Gedik N, Heusch G, Skyschally A. Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration. Arch Med Sci 2013; 9: 968-75.
65. De Paulis D, Chiari P, Teixeira G, et al. Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart. Basic Res Cardiol 2013; 108: 379.
66. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
67. Hausenloy Dj, Kunst G, Boston-Griffiths E, et al. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 2014; 100: 544-9.
68. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 1997; 79: 2-10.
69. Headrick JP, Ashton KJ, Rose'meyer RB, Peart JN. Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol Ther 2013; 140: 92-111.
70. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol Med 2013; 19: 345-54.
71. Köhler D, Eckle T, Faigle M, et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 2007; 116: 1784- 94.
72. Peart J, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 2007; 114: 208-21.
73. Williams-Pritchard G, Knight M, Hoe LS, Headrick JP, Peart JN. Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning. Am J Physiol Heart Circ Physiol 2011; 300: H2161-68.
74. Yitzhaki S, Huang C, Liu W, et al. Autophagy is required for preconditioning by the adenosine A1 receptor-selective agonist CCPA. Basic Res Cardiol 2009; 104: 157-67.
75. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006; 101: 311-8.
76. Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR, Linden J. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 2008; 295: H1825-33.
77. Xi J, McIntosh R, Shen X, et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 2009; 47: 684-90.
78. Yang X, Xin W, Yang XM, et al. A2B adenosine receptors inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes via a mechanism sensitive to Pertussis toxin. Br J Pharmacol 2011; 163: 995-06.
79. Koeppen M, Harter PN, Bonney S, et al. Adora2b signaling on bone marrow derived cells dampens myocardial ischemiareperfusion injury. Anesthesiology 2012; 116: 1245-57.
80. Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA. A3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol 2010; 49: 280-86.
81. de Jonge R, Out M, Maas WJ, de Jong JW. Preconditioning of rat hearts by adenosine A1 or A3 receptor activation. Eur J Pharmacol 2002; 441: 165-72.
82. Maddock HL, Mocanu MM, Yellon D. Adenosine A3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 2002; 283: H1307-13.
83. Germack R, Griffin M, Dickenson JM. Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. J Mol Cell Cardiol 2004; 37: 989-99.
84. Kin H, Zatta AJ, Lofye MT, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005; 67: 124-33.
85. Yang XM, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005; 100: 57-63.
86. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase Cadenosine A2B receptor cascade. Cardiovasc Res 2006; 70: 308-14.
87. Morrison RR, Tan XL, Ledent C, Mustafa SJ, Hofmann PA. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol 2007; 293: H2523-9.
88. Methner C, Schmidt K, Cohen MV, Downey JM, Krieg T. Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 2010; 299: H1262-64.
89. Lasley RD, Kristo G, Keith BJ, Mentzer RM Jr. The A2A/A2B receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol 2007; 292: H426-31.
90. Urmaliya VB, Pouton CW, Ledent C, Short JL, White PJ. Cooperative cardioprotection through adenosine A1 and A2A receptor agonism in ischemia reperfused isolated mouse heart. J Cardiovasc Pharmacol 2010; 56: 379-88.
91. Zhan E, McIntosh VJ, Lasley RD. Adenosine A A and A B receptors are both required for adenosine A receptor-mediated cardioprotection. Am J Physiol Heart Circ Physiol 2011; 301: H1183-9.
92. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711-20.
93. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD- II). J Am Coll Cardiol 2005; 45: 1775- 80.
94. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocrine Reviews 2006; 27: 762-8.
95. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol 2013; 216: T17-36.
96. Ding G, Qin Q, He N, et al. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J Mol Cell Cardiol 2007; 43: 73-84.
97. Amin RH1, Mathews ST, Alli A, Leff T. Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine mechanism. Am J Physiol Heart Circ Physiol 2010; 299: H690-8.
98. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-51.
99. Cheng KK, Lam KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007; 56: 1387- 94.
100. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008; 114: 361-74.
101. Wang Y, Lau WB, Gao E, et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 2010; 298: E663-70.
102. Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/ nitrative stress. Circulation 2007; 115: 1408-16.
103. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17: 55-63.
104. Chen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Cir Res 2009; 104: 496-505.
105. Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55: 1840-6.
106. Kim JE, Song SE, Kim YW, et al. Adiponectin inhibits palmitateinduced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol 2010; 207: 35-44.
107. Fujishima Y, Maeda N, Matsuda K, et al. Effect of adiponectin on cardiac β-catenin signaling pathway under angiotensin II infusion. Biochem Biophys Res Commun 2014; 444: 224-9.
108. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 2007; 102: 518-28.
109. Rastaldo R, Cappello S, Folino A, et al. Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol 2011; 300: H2308-15.
110. Regoli D, Plante GE, Gobeil F Jr. Impact of kinins in the treatment of cardiovascular diseases. Pharmacol Ther 2012; 135: 94-111.
111. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994; 270: 681-9.
112. Manolis AJ1, Marketou ME, Gavras I, Gavras H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res 2010; 33: 772-7.
113. Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res 2007; 75: 168-77.
114. Penna C, Mancardi D, Tullio F, Pagliaro P. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008; 103: 368-77.
115. Wang X, Wei M, Kuukasjarvi P, et al. The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). Scand Cardiovasc J 2009; 43: 72-9.
116. Pedersen CM, Schmidt MR, Barnes G, et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemiareperfusion injury in vivo in man. Heart 2011; 97: 1857-61.
117. Jin ZQ, Chen X. Pretreatment with ramiprilat induces cardioprotection against free radical injury in guinea-pig isolated heart: involvement of bradykinin, protein kinase C and prostaglandins. Clin Exp Pharmacol Physiol 2000; 27: 257-62.
118. Penna C, Tullio F, Moro F, Folino A, Merlino A, Pagliaro P. Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res Cardiol 2010; 105: 181-92.
119. Morris SD, Yellon DM. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol 1997; 29: 1599-06.
120. Jaberansari MT, Baxter GF, Muller CA, et al. Angiotensin converting enzyme inhibition enhances a subthreshold stimulus. to elicit delayed preconditioning in pig myocardium. J Am Coll Cardiol 2001; 37: 1996-01.
121. Kirkpatrick JN, St John Sutton M. Assessment of ventricular remodeling in heart failure clinical trials. Curr Heart Fail Rep 2012; 9: 328-36.
122. Ungi I, Palinkas A, Nemes A, et al. Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention. Can J Physiol Pharmacol 2008; 86: 827-34.
123. Zhao TC. Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol 2013; 12: 90.
124. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43- 52.
125. Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagonlike peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106-13.
126. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia reperfusion injury is attenuated by intact glucagon like peptide- 1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21: 253-6.
127. Zhao TC, Taher MM, Valerie KC, Kukreja RC. p38 Triggers late preconditioning elicited by anisomycin in heart: involvement of NF-kappaB and iNOS. Circ Res 2001; 89: 915-22.
128. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon- like peptide 1 can directly protect the heart against ischemia/ reperfusion injury. Diabetes 2005, 54: 146-51.
129. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation 2008, 117: 2340-50.
130. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001, 102: 81-6.
131. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ.GLP-1 and related peptides cause concentrationdependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008, 478: 136-42.
132. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide- 1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125: 173-7.
133. Liu J, Liu Y, Chen L, Wang Y, Li J. Glucagon-Like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J Diabetes Res 2013; 2013: 630537.
134. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007; 293: E460e5
135. Angelone T, Filice E, Quintieri AM, et al. Receptor identification and physiological characterization of glucagon-like peptide-2 in the rat heart. Nutr Metab Cardiovasc Dis 2012; 22: 486-94.
136. Penna C, Pasqua T, Perrelli MG, et al. Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels. Basic Res Cardiol 2012; 107: 272.
137. Zhang W, Zhu W, Zhang J, Li N, Li J. Protective effects of glucagon- like peptide 2 on intestinal ischemia-reperfusion rats. Microsurgery 2008; 28: 285-90.
138. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 2013; 1831: 203-12.
139. Knapp M. Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol 2011; 62: 601-7.
140. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-18.
141. Kelly-Laubscher RF, King JC, Hacking D, et al. Cardiac preconditioning with sphingosine-1-phosphate requires activation of signal transducer and activator of transcription-3. Cardiovasc J Afr 2014; 25: 118-23.
142. Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current Research on Opioid Receptor Function. Curr Drug Targets 2012; 13: 230-46.
143. Headrick JP, Pepe S, Peart JN. Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems. Current Pharmaceutical Design 2012; 18: 6090-100.
144. Borlongan CV, Wang Y, Su TP. Delta opioid peptide (d-ala 2, dleu 5) enkephalin: linking hiberation and neuroprotection. Front Biosci 2005; 9, 3392-8.
145. Zhang Y, Wu YX, Hao YB, Dun Y, Yang SP. Role of endogenous opioid peptides in protection of ischemic preconditioning in rat small intestine. Life Sci 2001; 68: 1013-9.
146. Addison PD, Neligan PC, Ashrafpour H, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol 2003; 285, H1435-43.
147. Romano MA, Seymour EM, Berry JA, McNish RA, Bolling SF. Relative contribution of endogenous opioids to myocardial ischemic tolerance. J Surg Res 2004; 118: 32-7.
148. Peart JN, Gross GJ. Exogenous activation of delta- and kappaopioid receptors affords cardioprotection in isolated murine heart. Basic Res Cardiol 2004; 99: 29-37.
149. Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268: H2157-61.
150. Lasukova TV, Krylatov AV, Maslov LN, et al. Antiarrhythmic and cardioprotective effect of stimulation of delta1-opiate receptors in myocardial ischemia and reperfusion. Patol Fiziol Eksp Ter 2004; (3): 12-5.
151. Maslov LN, Lishmanov YB, Oeltgen PR, et al. Activation of peripheral delta2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury Involvement of protein kinase C, NOsynthase, KATP channels and the autonomic nervous system. Life Sci 2009; 84: 657-63.
152. Rong F, Peng Z, Ye MX, et al. Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by kappa-opioid receptor agonist. Arch Med Res 2009; 40: 227-34.
153. Wang J, Gao Q, Shen J, Ye TM, Xia Q. Kappa-opioid receptor mediates the cardioprotective effect of ischemic postconditioning. Zhejiang Da Xue Xue Bao Yi Xue Ban 2007; 36: 41-7.
154. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-6.
155. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80: 1669-99.
156. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet- activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-45.
157. Stafforini DM, Mcintyre TM, Zimmerman GA, Prescott SM. Platelet- activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40: 643-72.
158. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood) 2011; 236: 390-401.
159. Detopoulou P, Nomikos T, Fragopoulou E, Chrysohoou C, Antonopoulou S. Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy. Curr Heart Fail Rep 2013; 10: 122-9.
160. Penna C, Alloatti G, Cappello S, et al. Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol 2005; 288: H2512- 20.
161. Penna C, Mognetti B, Tullio F, et al. The platelet activating factor triggers preconditioning-like cardioprotective effect via mitochondrial K-ATP channels and redox-sensible signaling. J Physiol Pharmacol 2008; 59: 47-54.
162. Penna C, Mognetti B, Tullio F, et al. Post-ischemic activation of kinases in the pre-conditioning-like cardioprotective effect of the platelet-activating factor. Acta Physiol 2009; 197: 175-85.
163. Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle 2010; 9: 4110-6.
164. Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV. Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab 2011; 22: 311-7.
165. Granata R, Isgaard J, Alloatti G, Ghigo E. Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood) 2011; 236: 505-14.
166. Granata R, Trovato L, Gallo MP, et al. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res 2009; 83: 303-12.
167. Penna C, Settanni F, Tullio F, et al. Growth hormone-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology 2013; 154: 1624-35.
168. Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A 2010; 107: 2604-9.
169. Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci U S A 2012; 109: 559-63.
170. JelkmannW. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-89.
171. Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G. Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int J Cardiol 2014; 171: 116-25.
172. Latini R, BrinesM, Fiordaliso F. Do non-hematopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 2008; 13: 415-23.
173. Wen Y, Zhang XJ, Ma YX, Xu XJ, Hong LF, Lu ZH. Erythropoietin attenuates hypertrophy of neonatal rat cardiac myocytes induced by angiotensin-II in vitro. Scand J Clin Lab Invest 2009; 69: 518-25.
174. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 2003; 100: 11612-7.
175. Prunier F, Pfister O, Hadri L, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007; 292: H522-9.
176. Tada H, Kagaya Y, Takeda M, et al. Endogenous erythropoietin system in nonhematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006; 71: 466- 77.
177. Asaumi Y, Kagaya Y, Takeda M, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007; 115: 2022-32.
178. Sterin-Borda L, Barcelo AC, Bozzini CE. Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol 2003; 121: 180- 6.
179. Shingo T, Sorokan ST, Shimazaki T,Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733- 43.
180. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340 - 6.
181. Stuckmann I, Evans S, Lasar AB. Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev Biol 2003; 255: 334- 49.
182. Wald MR, Borda ES, Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 1996; 167: 461-8.
183. Mastromarino V, Musumeci MB, Conti E, Tocci G, Volpe M. Erythropoietin in cardiac disease: effective or harmful? J Cardiovasc Med (Hagerstown) 2013; 14: 870-8.
184. Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost 2003; 1: 1587-92.
185. Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol 2014; 165: 259-68.
186. Stohlawetz P, Folman CC, von dem Borne AE, et al. Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999; 81: 613-7.
187. Lupia E, Spatola T, Cuccurullo A, et al. Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum. Basic Res Cardiol 2010; 105: 609-20.
188. Ramella R, Gallo MP, Spatola T, Lupia E, Alloatti G. A novel role of thrombopoietin as a physiological modulator of coronary flow. Regul Pept 2011; 167: 5-8.
189. Baker JE, Su J, Hsu A, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/ reperfusion in rats. Cardiovasc Res 2008; 77: 44-53.
190. Chan KY, Zhou L, Xiang P, et al. Thrombopoietin improved ventricular function and regulated remodeling genes in a rat model of myocardial infarction. Int J Cardiol; 2013; 167: 2546-54.
191. Li K, Sung RY, Huang WZ, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006; 113; 2211-20.
192. Chan KY, Xiang P, Zhou L, et al. Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. Eur J Heart Fail 2011; 13: 366-76.
193. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57: 660-71.
194. Belke DD, Betuing S, Tuttle MJ, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002; 109: 629-39.
195. Abel ED, O'Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 2012; 32: 2068-76.
196. O'Neill BT, Kim J, Wende AR, et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab 2007; 6: 294 -306.
197. Boudina S, Bugger H, Sena S, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009; 119: 1272-83.
198. Parra V, Verdejo HE, Iglewski M, et al. Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the AktmTOR- NFκB-Opa-1 signaling pathway. Diabetes 2014; 63: 75-88.
199. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: Effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 2003; 285: H1261 -9.
200. McQueen AP, Zhang D, Hu P, et al. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: Possible role of reduced capillary density. J Mol Cell Cardiol 2005; 39: 882 - 92.
201. Sena S, Hu P, Zhang D, et al. Impairedinsulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol 2009; 46: 910 -18.
202. Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010; 120: 1506-14.
203. Fullmer TM, Pei S, Zhu Y, et al. Insulin suppresses ischemic preconditioning- mediated cardioprotection through Akt-dependent mechanisms. J Mol Cell Cardiol 2013; 64: 20-9.
204. Baines CP, Wang L, Cohen MV, et al. Myocardial protection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 1999; 94: 188-98
205. Matsui T, Tao J, del Monte F, et al. Aactivation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104: 330-5.
206. Nagoshi T, Matsui T, Aoyama T, et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/ reperfusion injury. J Clin Invest 2005; 115: 2128-38.
207. Salminen PR, Dahle GO, Moen CA, et al. Intracoronary insulin administered at reperfusion in a porcine model of acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2014 pii: 2048872614547689. doi: 10.1177/2048872614547689.
208. Hausenloy DJ, Yellon DM. Cardioprotective growth factors. Cardiovasc Res 2009; 83: 179-94.
209. Lemmens K, Segers VF, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte crosstalk. J Biol Chem 2006; 281: 19469-77.
210. Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011; 123: 2254-62.
211. Burgess A, Cho H, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541-52.
212. Gallina C, Brero A, Gallo MP, Levi R. Regulation of intracellular cardiomyocyte calcium stores by peptides: a new approach to cardiac protection. Curr Med Chem 2012; 19: 5782-92.
213. Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail 2008; 14: 437-44.
214. Giraud M, Fluck M, Zuppinger C, Suter T. Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin- 1beta. J Appl Physiol 2005; 99: 313-22.
215. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2- dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006; 41: 228- 35.
216. Brero A, Ramella R, Fitou A, et al. Neuregulin-1ß1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res 2010; 88: 443-52.
217. Kuramochi Y, Cote G, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 2004; 279: 51141-7.
218. Fang SJ, Wu XS, Han ZH, et al. Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Chin Med J (Engl) 2004; 123: 3597-604.
219. Ebner B, Lange SA, Eckert T, et al. Uncoupled eNOS annihilates neuregulin-1β-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction. Mol Cell Biochem 2013; 373: 115-23.
220. Gao R, Zhang J, Cheng L, et al. Phase II, randomized, doubleblind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin- 1 in patients with chronic heart failure. J Am Coll Cardiol 2010; 55: 1907-14.
221. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-57.
222. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT J Cell Biol 2002; 159: 1029- 37.
223. Bedendi I, Alloatti G, Marcantoni A, et al. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des- Gln14 ghrelin. Eur J Pharmacol 2003; 476: 87-95.
224. Chang L, Ren Y, Liu X, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 2004; 43: 165-70.
225. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104: 2034-8.
226. Mitacchione G, Powers JC, Grifoni G, et al. The gut hormone ghrelin partially reverses energy substrate metabolic alterations in the failing heart. Circ Heart Fail 2014; 7: 643-51
227. Ozbay Y, Aydin S, Dagli AF, et al. Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease BMB Rep 2008; 41: 55-61.
228. Huda MS, Durham BH, Wong SP, et al. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond) 2008; 32: 129-35.
229. Xin X, Ren AJ, Zheng X, et al. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides 2009; 30: 2281-5.
230. Li J, Loukili N, Rosenblatt-Velin N, et al. Peroxynitrite is a key mediator of the cardioprotection afforded by ischemic postconditioning in vivo. PLoS One 2013 8: e70331.
231. Yang C, Liu Z, Liu K, Yang P. Mechanisms of Ghrelin anti-heart failure: inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression. PLoS One 2014; 9: e85785.
232. Alloatti G, Arnoletti E, Bassino E, et al. Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 2010; 299: H470-81.
233. Aragno M, Mastrocola R, Ghé C, Arnoletti E, Bassino E, Alloatti G, Muccioli G. Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol 2012; 11: 129.
234. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; 191: 341-66.
235. Baertschi AJ, Hausmaninger C, Walsh RS, Mentzer RM, Wyatt DA, Pence RA. Hypoxia-induced release of atrial natriuretic factor (ANF) from the isolated rat and rabbit heart. Biochem Biophys Res Commun 1986; 140: 427-33.
236. Chun YS, Hyun JY, Kwak YG, et al. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 2003; 370: 149- 57.
237. Weidemann A, Klanke B, Wagner M, et al. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretici peptide induction. Biochem J 2008; 409: 233-42.
238. Del Ry S, Cabiati M, Clerico A. Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure. Pharmacol Res 2013; 76: 190-8.
239. Lukowski R, Krieg T, Rybalkin SD, Beavo J, Hofmann F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. Trends Pharmacol Sci 2014; 35: 404-13.
240. DeGeorge BR Jr, Gao E, Boucher M, et al. Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 2008; 117: 1378-87.
241. D'Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003; 284: H1592-600.
242. Sangawa K, Nakanishi K, Ishino K, Inoue M, Kawada M, Sano S. Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 2004; 77: 233-7.
243. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium derived C-type natriuretic peptide. Circulation 2004; 110: 1231-5.
244. Houng AK, McNamee RA, Kerner A, et al. Atrial natriuretic peptide increases inflammation, infarct size, and mortality after experimental coronary occlusion. Am J Physiol Heart Circ Physiol 2009; 296: H655-61.
245. De Celle T, Vanrobaeys F, Lijnen P, et al. Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia-reperfusion. Exp Physiol 2005; 90: 593- 606.
246. Kuhn M, Völker K, Schwarz K, et al. The natriuretic peptide/ guanylyl cyclase-a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 2009; 119: 2019- 30.
247. Lyu T, Zhao Y, Zhang T, et al. Natriuretic peptides as an adjunctive treatment for acute myocardial infarction: insights from the meta-analysis of 1,389 patients from 20 trials. Int Heart J 2014; 55: 8-16.
248. Caliendo G, Cirino G, Santagada V, Wallace JL. Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S releasing drugs as pharmaceuticals. J Med Chem 2010; 53: 6275- 86.
249. Szabo C. Gaseotransmitters: New frontiers for translational science. Sci Transl Med 2010; 2: 59ps54.
250. Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, Ferdinandy P. The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol 2015; 172: 1587-606.
251. Muchova L, Wong RJ, Hsu M, et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 2007 85: 800-10.
252. Zhang Y, Tocchetti CG, Krieg T, Moens AL. Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radic Biol Med 2012; 53: 1531-40.
253. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003; 138: 532-43.
254. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-58.
255. Heinrich TA, da Silva RS, Miranda KM, Switzer CH, Wink DA, Fukuto JM. Biological nitric oxide signalling: chemistry and terminology. Br J Pharmacol 2013; 169: 1417-29.
256. Calvert JW, Condit ME, Aragón JP, et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of β(3)- adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 2011; 108: 1448-58.
257. Farah C1, Kleindienst A, Bolea G, et al. Exercise-induced cardioprotection: a role for eNOS uncoupling and NO metabolites. Basic Res Cardiol 2013; 108: 389.
258. Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 2014; 114: 1601-10.
259. Tong G, Aponte AM, Kohr MJ, Steenbergen C, Murphy E, Sun J. Postconditioning leads to an increase in protein S-nitrosylation. Am J Physiol Heart Circ Physiol 2014; 306: H825-32.
260. Kupai K, Csonka C, Fekete V, et al. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 2009; 297: H1729-35.
261. Fan Q, Yang XC, Liu Y, et al. Postconditioning attenuates myocardial injury by reducing nitro-oxidative stress in vivo in rats and in humans. Clin Sci (Lond) 2011; 120: 251-61.
262. Methner C, Lukowski R, Grube K, et al. Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 2013; 108: 337.
263. Chouchani ET, Methner C, Nadtochiy SM, et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat Med 2013; 19: 753-59.
264. Sun J, Murphy E. Protein S-nitrosylation and cardioprotection. Circ Res 2010; 106: 285-96.
265. Lynn EG, Austin RC. Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. Expert Rev Clin Pharmacol 2011; 4: 97-108.
266. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012; 92 791-896.
267. Arakawa M, Yasutake M, Miyamoto M, Takano T, Asoh S, Ohta S. Transduction of anti-cell death protein FNK protects isolated rat hearts from myocardial infarction induced by ischemia/reperfusion. Life Sci 2007; 80: 2076-84.
268. Geng B, Yang J, Qi Y, et al. H2S generated by heart in rat and its effects on cardiac function. Biochem Biophys Res Commun 2004; 313: 362-8.
269. Bliksoen M, Kaljusto ML, Vaage J, Stenslokken KO. Effects of hydrogen sulphide on ischaemia-reperfusion injury and ischaemic preconditioning in the isolated, perfused rat heart. Eur J Cardiothorac Surg 2008; 34: 344-9.
270. Elsey DJ, Fowkes RC, Baxter GF. L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 2010; 15: 53-9.
271. Elrod JW, Calvert JW, Morrison J, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA 2007; 104: 15560-5.
272. King AL, Polhemus DJ, Bhushan S, et al. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A, 2014; 111: 3182-87.
273. Bian JS, Yong QC, Pan TT, et al. Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther 2006; 316: 670- 8.
274. Pan TT, Feng ZN, Lee SW, Moore PK, Bian JS. Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. J Mol Cell Cardiol 2006; 40: 119-30.
275. Yong QC, Lee SW, Foo CS, Neo KL, Chen X, Bian J-S. Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol 2008; 295: H1330-H40.
276. Huang YE, Tang ZH, Xie W, et al. Endogenous hydrogen sulfide mediates the cardioprotection induced by ischemic postconditioning in the early reperfusion phase. Exp Ther Med 2012; 4: 1117-23.
277. Scragg JL, Dallas ML, Wilkinson JA, Varadi G, Peers C. Carbon monoxide inhibits L-type Ca2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. J Biol Chem 2008; 283: 24412-19.
278. King AL, Polhemus DJ, Bhushan S, et al. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A. 2014; 111: 3182-7.
279. Johnson RA, Teran FJ, Durante W, Peyton KJ, Johnson FK. Enhanced heme oxygenase-mediated coronary vasodilation in Dahl salt-sensitive hypertension. Am J Hypertens 2004; 17: 25-30.
280. Stein AB, Bolli R, Dawn B, et al. Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol 2012; 52: 228-36.
281. Foresti R, Goatly H, Green CJ, Motterlini R. Role of heme oxygenase- 1 in hypoxia-reoxygenation: requirement of substrate heme to promote cardioprotection. Am J Physiol Heart Circ Physiol 2001; 281: H1976-84.
282. Czibik G, Sagave J, Martinov V, et al. Cardioprotection by hypoxia- inducible factor 1 alpha transfection in skeletal muscle is dependent on haem oxygenase activity in mice. Cardiovasc Res 2009; 82: 107-14.
283. Yet SF, Tian R, Layne MD, et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001; 89: 168-73.
284. Yoshida T, Maulik N, Ho YS, Alam J, Das DK. H(mox-1) constitutes an adaptive response to effect antioxidant cardioprotection: A study with transgenic mice heterozygous for targeted disruption of the heme oxygenase-1 gene. Circulation 2001; 103: 1695-701.
285. Zhu JC, Shao JL, Ma H, Wang JK. Interaction between endogenous cystathionine synthase/hydrogen sulfide and heme oxygenase- 1/carbon monoxide systems during myocardial ischemicreperfusion: experiment with rats. Zhonghua Yi Xue Za Zhi 2008; 88: 3222-55.
286. Gonzales MA, Mascharak PK. Photoactive metal carbonyl complexes as potential agents for targeted CO delivery. J Inorg Biochem 2014; 133: 127-35.
287. Zobi F. CO and CO-releasing molecules in medicinal chemistry. Future Med Chem 2013; 5: 175-188.
288. Romão CC, Blättler WA, Seixas JD, Bernardes GJ. Developing drug molecules for therapy with carbon monoxide. Chem Soc Rev 2012; 41: 3571-83.
289. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 2010; 9: 728-743
290. Kondo-Nakamura M, Shintani-Ishida K, Uemura K, Yoshida K. Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. Biochem Biophys Res Commun 2010; 393: 449-54.
291. Lin HH, Chen YH, Chiang MT, Huang PL, Chau LY. Activator protein-2α mediates carbon monoxide-induced stromal cell-derived factor-1α expression and vascularization in ischemic heart. Arterioscler Thromb Vasc Biol 2013; 33: 785-794
292. Queiroga CS, Almeida AS, Martel C, Brenner C, Alves PM, Vieira HL. Glutathionylation of adenine nucleotide translocase induced by carbon monoxide prevents mitochondrial membrane permeabilization and apoptosis. J Biol Chem 2010; 285: 17077-88.
293. Soni HM, Jain MR, Mehta AA. Mechanism(s) involved in carbon monoxide-releasing molecule-2-mediated cardioprotection during ischaemia-reperfusion injury in isolated rat heart. Indian J Pharm Sci 2012; 74: 281-91.
294. Soni H, Patel P, Rath AC, Jain M, Mehta AA. Cardioprotective effect with carbon monoxide releasing molecule-2 (CORM-2) in isolated perfused rat heart: Role of coronary endothelium and underlying mechanism. Vascul Pharmacol 2010; 53: 68-76.
295. Stein AB, Guo Y, Tan W, et al. Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol 2005; 38: 127-34.
296. Zhang J, Piantadosi CA. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 1992; 90: 1193-99.
297. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med 2002; 7: 195-202.
298. Peyton KJ, Reyna SV, Chapman GB, et al. Heme oxygenase-1- derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. Blood 2002; 99: 4443-8
299. Meyer G, André L, Tanguy S, et al. Simulated urban carbon monoxide air pollution exacerbates rat heart ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2010; 298: H1445-53.
300. Andre L, Boissière J, Reboul C, et al. Carbon monoxide pollution promotes cardiac remodeling and ventricular arrhythmia in healthy rats. Am J Respir Crit Care Med 2010; 181: 587-95.
301. Dallas ML, Yang Z, Boyle JP, et al. Carbon monoxide induces cardiac arrhythmia via induction of the late Na+ current. Am J Respir Crit Care Med 2012; 186: 648-56.
302. Tota B, Angelone T, Cerra MC. The surging role of Chromogranin A in cardiovascular homeostasis. Front Chem 2014; 2: 64.
303. Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan- dependent mechanism. J Cell Biochem 2010; 110: 70-9.
304. Fornero S, Bassino E, Ramella R, et al. Obligatory role for endothelial heparan sulphate proteoglycans and caveolae internalization in catestatin-dependent eNOS activation. Biomed Res Int 2014; 2014: 783623.
305. Cappello S, Angelone T, Tota B, et al. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 2007; 293: H719-27.
306. Yu M, Wang Z, Fang Y, et al. Overexpression of vasostatin-1 protects hypoxia/reoxygenation injuries in cardiomyocytes independent of endothelial cells. Cardiovasc Ther 2012; 30: 145-51.
307. Liu J, Yang D, Shi S, et al. Overexpression of vasostatin-1 protects hypoxia/reoxygenation injuries in cardiomyocytes-endothelial cells transwell co-culture system. Cell Biol Int 2014; 38: 26-31.
308. Penna C, Alloatti G, Gallo MP, et al. Catestatin improves postischemic left ventricular function and decreases ischemia/ reperfusion injury in heart. Cell Mol Neurobiol 2010; 30: 1171-9.
309. Brar BK, Helgeland E, Mahata SK, et al. Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept 2010; 165: 63-70.
310. Perrelli MG, Tullio F, Angotti et al. Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling. Pflugers Arch 2013; 465: 1031-40.
311. Yellon DM, Davidson SM. Exosomes: nanoparticles involved in cardioprotection? Circ Res 2014; 114: 325-32.
312. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010; 4: 214-22.
313. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 2014; 103: 530-41.
314. Chen L, Wang Y, Pan Y, et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/ reperfusion injury. Biochem Biophys Res Commun 2013; 431: 566-71.
315. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2014; 2: 606-19.
316. Giricz Z, Varga ZV, Baranyai T, et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol 2014; 68: 75-8.
317. Bell R, Beeuwkes R, Bøtker HE, et al. Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 2012; 107: 300.
318. Garcia-Dorado D, Otaegui I, Rodriguez Palmoares JF, et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI. Europ Heart J 2013; 34 (suppl 1): 669-70.
319. Wong GT, Huang Z, Ji S, Irwin MG. Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 2010; 24: 790-6.
320. Obame FN, Zini R, Souktani R, Berdeaux A, Morin D. Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J Pharmacol Exp Ther 2007; 323: 336-45.
321. Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV. Triple therapy greatly increases myocardial salvage during ischemia/ reperfusion in the in situ rat heart. Cardiovasc Drugs Ther 2013; 27: 403-12.
322. Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can J Anaesth 2002; 49: 777-91.
323. Zaugg M, Lucchinetti E, Behmanesh S, Clanachan AS. Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications. Curr Pharm Des 2014; 20: 5706-26.
324. McAlister FA. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 2012; 33: 505-14.
325. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013; 61: 131-42.
326. Lim SY, Hausenloy DJ. Remote ischemic conditioning: from bench to bedside. Front Physiol 2012; 3: 27.
327. Sala-Mercado JA, Wider J, Undyala VVR, et al. Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. Circulation 2010; 122: S179-84.
328. Shiomi M, Miyamae M, Takemura G, et al. Induction of autophagy restores the loss of sevoflurane cardiac preconditioning seen with prolonged ischemic insult. Eur J Pharmacol 2014; 724: 58-66.
329. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet 2007; 370: 575-9.
330. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375: 727- 34.
331. Thielmann M, Kottenberg E, Boengler K, et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 2010; 105: 657-64.
332. Davies WR, Brown AJ, Watson W, et al. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: The CRISP Stent Trial Long-Term Follow- Up. Circ Cardiovasc Interv 2013; 6: 246-51.
333. Thielmann M, Kottenberg E, Kleinbongard P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 2013; 382: 597- 604.
334. Sloth AD, Schmidt MR, Munk K, et al. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 2014; 35: 168-75.
335. Heusch G. Remote conditioning: the future of cardioprotection? J Cardiovasc Med (Hagerstown) 2013; 14: 176-9.
336. Tissier R, Hamanaka K, Kuno A, Parker JC, Cohen MV, Downey JM. Total liquid ventilation provides ultra-fast cardioprotective cooling. J Am Coll Cardiol 2007; 49: 601-5.
337. Miki T, Liu GS, Cohen MV, Downey JM. Mild hypothermia reduces infarct size in the beating rabbit heart: a practical intervention for acute myocardial infarction? Basic Res Cardiol 1998; 93: 372-83.
338. Miura T, Ogawa T, Suzuki K, Goto M, Shimamoto K. Infarct size limitation by a new Na+-H+ exchange inhibitor, Hoe 642: difference from preconditioning in the role of protein kinase C. J Am Coll Cardiol 1997; 29: 693-701.
339. Xu Z, Downey JM, Cohen MV. Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis 2003; 5: 368-71.
340. Xu Z, Jiao Z, Cohen MV, Downey JM. Protection from AMP 579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart. J Cardiovasc Pharmacol 2002; 40: 510-8.